Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Sandra Gurdain"'
Autor:
Renaud Louis, Charles Pilette, Olivier Michel, Alain Michils, Guy Brusselle, Antoine Poskin, Jan Van Schoor, Kris Denhaerynck, Stefaan Vancayzeele, Ivo Abraham, Sandra Gurdain
Publikováno v:
Allergy, Asthma & Clinical Immunology, Vol 15, Iss 1, Pp 1-9 (2019)
Abstract Background Immunoglobulin E (IgE) is the treatment target of omalizumab, a monoclonal antibody indicated in the treatment of severe allergic asthma. Long-term variability of serum total IgE (sIgEtot) in asthmatics remains poorly documented.
Externí odkaz:
https://doaj.org/article/7a4af88e2e29494bb8a7b297e43013c6
Autor:
Alain Michils, Kris Denhaerynck, Stefaan Vancayzeele, Guy Brusselle, Antoine Poskin, Charles Pilette, Ivo Abraham, Jan Van Schoor, Sandra Gurdain, Olivier Michel, Renaud Louis
Publikováno v:
Allergy, Asthma & Clinical Immunology, Vol 15, Iss 1, Pp 1-9 (2019)
ALLERGY ASTHMA AND CLINICAL IMMUNOLOGY
Allergy, asthma, and clinical immunology, 15
Allergy, asthma, and clinical immunology, Vol. 15, no.1, p. 20 [1-9] (2019)
Allergy, Asthma, and Clinical Immunology : Official Journal of the Canadian Society of Allergy and Clinical Immunology
ALLERGY ASTHMA AND CLINICAL IMMUNOLOGY
Allergy, asthma, and clinical immunology, 15
Allergy, asthma, and clinical immunology, Vol. 15, no.1, p. 20 [1-9] (2019)
Allergy, Asthma, and Clinical Immunology : Official Journal of the Canadian Society of Allergy and Clinical Immunology
Immunoglobulin E (IgE) is the treatment target of omalizumab, a monoclonal antibody indicated in the treatment of severe allergic asthma. Long-term variability of serum total IgE (sIgEtot) in asthmatics remains poorly documented.
SCOPUS: ar.j
SCOPUS: ar.j
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3d325438b2a2f3410df0778bd1af8250
http://link.springer.com/article/10.1186/s13223-019-0331-8
http://link.springer.com/article/10.1186/s13223-019-0331-8
Publikováno v:
Allergy and immunology.
Background: In patients with a diagnosis of asthma, there is currently no consensus which allergy tests should be performed to confirm a diagnosis of allergy. Aims and Objectives: We aimed to gain insight in the decision making in allergy testing in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8e5c91c1139d2fa5431820a0d1110234
https://doi.org/10.1183/13993003.congress-2020.1098
https://doi.org/10.1183/13993003.congress-2020.1098
Publikováno v:
Allergy and immunology.
Background: In patients with asthma, there is currently no clear consensus which tests should be performed to confirm a diagnosis of allergy. Aims and Objectives: We aimed to gain insights in the decision making in allergy testing in patients with as
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bf21328a5b9e6b6a062acd757c8b3eda
https://doi.org/10.1183/13993003.congress-2020.242
https://doi.org/10.1183/13993003.congress-2020.242
Autor:
Guy Joos, Evelyne Vanvlasselaer, Walter Vincken, An Lehouck, Vincent Ninane, Sandra Gurdain, Paul Germonpré, Giuseppe Liistro, Wim Janssens, Jean-Louis Corhay
Publikováno v:
International Journal of Chronic Obstructive Pulmonary Disease, Vol. Volume 12, no.12, p. 793-801 (2017)
International Journal of Chronic Obstructive Pulmonary Disease
INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE
International journal of chronic obstructive pulmonary disease, 12
International Journal of Chronic Obstructive Pulmonary Disease
INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE
International journal of chronic obstructive pulmonary disease, 12
Background: Global Initiative for Chronic Obstructive Lung Disease (GOLD) global strategy (2015) provides guidance for the treatment of chronic obstructive pulmonary disease (COPD) with different first-choice options per GOLD category without specifi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0eee69abe3434ab69e7af64a157dd725
https://hdl.handle.net/2078.1/220251
https://hdl.handle.net/2078.1/220251
Autor:
Alain Michils, Sandra Gurdain, Antoine Poskin, Lieven Dupont, Guy Brusselle, Olivier Michel, Charles Pilette, Jan Van Schoor, Renaud Louis, Stefaan Vancayzeele
Publikováno v:
5.2 Monitoring Airway Disease.
Long-term variability of serum total IgE (sIgE tot ) has been reported in asthmatics. This study evaluates the dynamics and the factors predictive of this variability. sIgE tot levels were prospectively measured over 1 year in 41 moderate-to-severe a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::75af52e987aab5a2c6c1a19537c1d79b
https://doi.org/10.1183/13993003.congress-2016.pa4171
https://doi.org/10.1183/13993003.congress-2016.pa4171
Autor:
Antoine Poskin, Paul Van den Brande, Stefaan Vancayzeele, Sandra Gurdain, Jan Van Schoor, Walter Vincken
Publikováno v:
5.1 Airway Pharmacology and Treatment.
Onbrace is a Belgian non-interventional study evaluating the use of indacaterol (IND), a long-acting β 2 agonist indicated for COPD maintenance treatment. Known COPD patients requiring the initiation of maintenance inhaled treatment i) with IND used
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7ea056d8b8d9597584ac4da562d0b051
https://doi.org/10.1183/13993003.congress-2016.pa4074
https://doi.org/10.1183/13993003.congress-2016.pa4074
Autor:
Alain Michils, Antoine Poskin, Stefaan Vancayzeele, Jan Van Schoor, Sandra Gurdain, Muriel Lins
Publikováno v:
5.1 Airway Pharmacology and Treatment.
Omalizumab (OMA) (Xolair ® ) is an anti-IgE monoclonal antibody indicated for the maintenance treatment of persistent severe allergic asthma (PSAA). OMA treatment requires (once/twice) monthly injections causing concerns for persistence and adherenc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c2b710632632f10d3b0fd337905cc01d
https://doi.org/10.1183/13993003.congress-2016.pa4122
https://doi.org/10.1183/13993003.congress-2016.pa4122
Autor:
MinKyoung Song, Ivo Abraham, Guy Brusselle, Alain Michils, Sandra Gurdain, Christine Hermans, Stefaan Vancayzeele, Lieven Dupont, Christopher S. Lee, Renaud Louis, Charles Pilette, P. Lecomte, A. Delobbe, Karen MacDonald, B. Van de Maele
Publikováno v:
Respiratory Medicine. (11):1633-1642
SummaryObjectiveTo evaluate the 16- and 52-week effectiveness of add-on omalizumab treatment under real-life heterogeneity in patients, settings, and physicians in an open-label, multicenter, pharmaco-epidemiologic study of patients with severe persi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b4edaa9c55667761a6465bf5cfc0b53e